Zura Bio’s (ZURA) Buy Rating Reiterated at Guggenheim

Guggenheim reissued their buy rating on shares of Zura Bio (NASDAQ:ZURA) in a research report report published on Wednesday,Benzinga reports. They currently have a $15.00 price target on the stock.

A number of other research analysts have also issued reports on ZURA. HC Wainwright reiterated a “neutral” rating and issued a $5.00 target price on shares of Zura Bio in a report on Tuesday, December 24th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. Finally, Chardan Capital cut their target price on shares of Zura Bio from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $15.00.

Zura Bio Price Performance

Shares of ZURA opened at $1.27 on Wednesday. The company’s 50-day simple moving average is $1.46 and its 200-day simple moving average is $2.73. Zura Bio has a 1 year low of $1.07 and a 1 year high of $6.35.

Zura Bio (NASDAQ:ZURA) last released its earnings results on Tuesday, March 25th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.09. The business had revenue of $0.00 million for the quarter. As a group, sell-side analysts anticipate that Zura Bio will post -0.65 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zura Bio

Hedge funds and other institutional investors have recently made changes to their positions in the business. American Century Companies Inc. acquired a new position in Zura Bio in the fourth quarter valued at approximately $27,000. Prudential Financial Inc. acquired a new position in shares of Zura Bio in the 4th quarter valued at $28,000. Two Sigma Advisers LP acquired a new position in shares of Zura Bio in the 4th quarter valued at $32,000. ProShare Advisors LLC purchased a new position in shares of Zura Bio in the 4th quarter valued at $35,000. Finally, XTX Topco Ltd acquired a new stake in Zura Bio during the 4th quarter worth $44,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.